COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research.
With in-person teaching in hospital and clinic settings suspended as the COVID-19 pandemic emerged, Weill Cornell Medical College swiftly designed innovative telehealth courses that enabled medical students to take part in remote patient care while also positioning them for post-pandemic careers with expanded digital healthcare options.
Women who receive COVID-19 mRNA vaccines produced by Pfizer-BioNTech or Moderna while in their third trimester of pregnancy generate a strong immune response and pass protective antibodies through umbilical cord blood to their babies.
With vaccine availability growing in New York City and across the country, attention is increasingly turning to those who are eligible but hesitant about getting the shot
Two distinct diagnostic tests, a host/pathogen RNA sequencing platform, and spatially-resolved tissue mapping tools were created by a multidisciplinary team of Weill Cornell Medicine and NewYork-Presbyterian Hospital-led researchers and used to map SARS-CoV-2 infections at the height of the initial COVID-19 outbreak in New York City.
A team led by investigators at Weill Cornell Medicine and NewYork-Presbyterian has used advanced technology and analytics to map, at single-cell resolution, the cellular landscape of diseased lung tissue in severe COVID-19 and other infectious lung diseases.
Last spring, as the COVID-19 pandemic hit New York City with full force, Dr. Daniel MacGowan, a neurologist specializing in neuromuscular disease, was asked to consult in a COVID recovery ward.
As the COVID-19 pandemic enters its second year, scientists are urgently investigating ways to detect signs of the SARS-CoV-2 virus before an outbreak emerges.
Antibodies that guard against COVID-19 can transfer from mothers to babies while in the womb, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian researcher.
Severe COVID-19 involves a distinctive reprogramming of gene activity in infected patients‘ immune cells, according to a study led by researchers at Weill Cornell Medicine.
With the COVID-19 vaccines rolling out across the country and more people getting vaccinated, many are wondering how long it takes for the vaccines to provide protection.
Cases of symptomatic COVID-19 were extremely low among children and staff at a network of YMCA day camps in North Carolina that took precautions like masking and physical distancing, with close to zero transmissions occurring at the camps.
As the coronavirus vaccine rolls out across the country, an infectious disease expert answers questions about its safety and when it’s likely to be available to the general public.
Human organoids, tiny organ-like structures grown in the laboratory, can be used to identify potential COVID-19 drugs in an automated, high-throughput fashion.
T-cells taken from the blood of people who recovered from a COVID-19 infection can be successfully multiplied in the lab and maintain the ability to effectively target proteins that are key to the virus’s function.
When a patient is hospitalized with COVID-19, signs of damage to the right side of the heart may indicate a greater risk of death, according to a study from investigators at Weill Cornell Medicine and NewYork-Presbyterian.
